• Bulletin of the Korean Chemical Society
• /
• 제35권11호
• /
• pp.3156-3157
• /
• 2014

• 대한한의학회지
• /
• 제29권3호
• /
• pp.124-130
• /
• 2008

Herbal plants or traditional Oriental medicine have been considered as a potential resource of new drug development worldwide. However, traditional Korean medicine has given little effort to the field of new drug development. This study reports on a plant-derived hepatotherapeutic drug, silymarin, which has been popularly used in many countries. It was discovered as an active compound from Silybum marianum (milk thistle) which has been known as a medicinal plant having hepatoprotective properties in both European and Asian countries. While it has been used as an herbal prescription in Asia, its active compounds or scientific mechanisms were intensively studied in Europe. Currently, silymarin is one of the most powerful herbal extracts in the world, and its usage is being expanded to many other medical purposes. This report would be helpful for providing an informative example of herbal-derived drug development to Oriental doctors or scientists in the Oriental medicinal field.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1998년도 Proceedings of UNESCO-internetwork Cooperative Regional Seminar and Workshop on Bioassay Guided Isolation of Bioactive Substances from Natural Products and Microbial Products
• /
• pp.114-117
• /
• 1998

Chinese traditional drugs have a long history to be used in clinics to treat various diseases and are confirmed to be effective approach through thousands of years of medical practice. Therefore, as a common understanding, the drug development from traditional Chinese medicines could be considered as a “shortcut” way with less blindness and more saving of time and money since development of new Chinese drugs has a different approach from that of western new drugs. Firstly, Chinese new drug development can be simplified as “from men to animal” process rather than “from animal to men” in western medicines. Hence the successful rate would be higher. Secondly, the original drugs or prescriptions from which the new drugs are planned to develop have been known what symptoms they are indicated for. Therefore, the developing procedure is actually a refine process with much less blindness than that of western drugs.

• 한국식품위생안전성학회지
• /
• 제28권2호
• /
• pp.181-187
• /
• 2013

전분의 사용원료를 확인하는 방법은 전분입자의 크기 또는 형태 등으로 분류하는 이화학적인 방법이 연구되었으나 원료별 또는 동일한 원료라도 품종에 따른 차이점으로 인하여 명확하게 확인하기 어려운 단점이 있어 유전자분석법을 시도하였다. 시료는 고구마 전분, 감자 전분, 옥수수 전분 및 타피오카 전분 등 총 11종을 사용하였으며, 유전자추출은 DNeasy plant mini 키트, magnetic DNA purification system 및 CTAB 방법으로 하였으며 추출유전자의 증폭을 위하여 WGA 키트로 처리하였다. 그리고 고구마, 감자, 옥수수 및 타피오카 검출을 위한 유전자 부위는 SSR (simple sequence repeat, ib-286-F/ib-286-R), 자당합성효소(potato sucrose synthase, Pss 01n-5'/Pss 01n-3'), 전분합성효소(starch synthase, SSllb 3-5'/SSllb 3-3') 및 SSR (SSRY26-F/SSRY26-R)를 각각 사용하였다. 그 결과 대부분의 경우 WGA를 처리한 경우에는 사용원료의 확인이 가능하였다.

• Interdisciplinary Bio Central
• /
• 제2권4호
• /
• pp.9.1-9.5
• /
• 2010

Many neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, are devastating disorders that affect millions of people worldwide. However, the number of therapeutic options remains severely limited with only symptomatic management therapies available. With the better understanding of the pathogenesis of neurodegenerative diseases, discovery efforts for disease-modifying drugs have increased dramatically in recent years. However, the process of translating basic science discovery into novel therapies is still lagging behind for various reasons. The task of finding new effective drugs targeting central nervous system (CNS) has unique challenges due to blood-brain barrier (BBB). Furthermore, the relatively slow progress of neurodegenerative disorders create another level of difficulty, as clinical trials must be carried out for an extended period of time. This review is intended to provide molecular and cell biologists with working knowledge and resources on CNS drug discovery and development.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권1호
• /
• pp.87-90
• /
• 2012

Cholangiocarcinoma (CCA) is the most common cancer in northeastern Thailand. At present, effective diagnosis of CCA either in humans or animals is not available. Monitoring the development and progression of CCA in animal models is essential for research and development of new promising chemotherapeutics. Ultrasonography has been widely used for screening of bile duct obstruction in CCA patients. In this study, we preliminarily investigated the applicability of ultrasonography to monitor the development and progression of CCA in Syrian golden hamsters (n=8) induced by Opisthorchis viverrini (OV)/dimethylnitrosamine (DMN) administration. Ultrasonography and histopathological examination of hamsters was performed at week 0, 20, 24 and 28 of OV infection or at the start of water/Tween-80 administration to controls. The ultrasonographic images of liver parenchyma and gallbladders of OV/DMN-induced CCA hamsters showed sediments in gallbladder, thickening of gallbladder wall, and hypoechogenicity of liver parenchyma cells. The ultrasonographic images of liver tissues were found to correlate well with histopathological examination. Although ultrasonography does not directly detect the occurrence of CCA, it reflects the thickening of bile ducts and abnormality of liver tissues. It may be applied as a reliable tool for monitoring the development and progression of CCA in animal models in research and development of new promising chemotherapeutics for CCA.

• 대한예방한의학회지
• /
• 제5권1호
• /
• pp.57-75
• /
• 2001

This study was conducted to improve the current regulation guidelines for developing traditional Korean medicines with effectiveness and productivity, in order to cope with the upcoming ICH on specifications on oriental herbal drugs. Also, major purposes of this study are to motivate R&D and to pioneer foreign markets for domestic herbal drug companies. First, after examining concepts of traditional Korean medicines and comparing the numbers and differentiation of herbal drugs registered on Pharmacopeia among Korea, China, and Japan, the current new drug development requirements for traditional Korean medicines were reviewed in detail, followed by comparison of foreign regulation systems including USA, EU, China, and Japan. Second, empirical cases on failure of development for new traditional Korean medicines under the current regulation system in the domestic companies including Dong-A, Kwangdong, and Samchondang, were collected and analyzed. As a result, hanbangsaengyak, the new category for traditional Korean medicines was newly developed on the basis of scientification of data between saengyak and hanyak, from the perspectives of harmonization between oriental medicine and western medicine and of balance between food and drug, in terms of industrialization, publicity, modernization, and effectiveness of administration. In addition, the new regulation requirements for the new hanbangsaengyak preparations were discussed by establishing principles of reinforcing preclinical test and of simplifying clinical trials in Korea. Finally, the further researches to articulate the complete specifications for pre-clinical and clinical requirements for traditional Korean medicines were strongly suggested.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1993년도 제2회 신약개발 연구발표회 초록집
• /
• pp.34-35
• /
• 1993

The Development of new asymmetric induction methods useful for syntheses of biologically active natural products and drugs, using C4-chiral 1,3-th-iazolidine-2-thiones, has been a recent focus of interest. 1-8) The present account describes the significance of particular heterocycles in the synthetic development of new 1${\beta}$-substituted carbapenems. A fungal metabolite, (＋)-thienamycin (1) has attracted one's attention as a hopeful candidate for new-generation antibiotic drugs because of its strong antimicrobial activities and wide antimicrobial spectra due to the extensive inhibition against various ${\beta}$-lactamases. However, it has been serious problems toward a practically useful drug that (＋)-thienamycin is fairly labile in the solution and can be metabolized by renal dehydropept- idase-I (DHP-I). Recently, a Merck Sharp ＆ Dohme research group exploited a non-natural ${\beta}$-lactam, imipenem (2) which has been appeared in the drug market as the first carbapenem-type antibiotic drug. 9) However 2 must be used with a DHP-I inhibitor, cilastatin sodium (3).9) Thus, a 1,${\beta}$-methyl- carbapenem derivative 4 has been disclosed by the same group. 10) It seems to be more hopeful candidate as a new-generation antibiotic because it can directly resist against metabolism by the renal DHP-1 without an enzyme inhibitor 3. 10)

• 한국컴퓨터정보학회논문지
• /
• 제22권3호
• /
• pp.131-138
• /
• 2017

New drug development is time-consuming and costly. Hence, it is necessary to repurpose old drugs for finding new indication. We suggest the way that repurposing old drug using massive literature data and biological network. We supposed a disease-drug relationship can be available if signal pathways of the relationship include significant genes identified in literature data. This research is composed of three steps-identifying significant gene using co-occurrence in literature; analyzing the shortest path on biological network; and scoring a relationship with comparison between the significant genes and the shortest paths. Based on literatures, we identify significant genes based on the co-occurrence frequency between a gene and disease. With the network that include weight as possibility of interaction between genes, we use shortest paths on the network as signal pathways. We perform comparing genes that identified as significant gene and included on signal pathways, calculating the scores and then identifying the candidate drugs. With this processes, we show the drugs having new possibility of drug repurposing and the use of our method as the new method of drug repurposing.

• Journal of Microbiology and Biotechnology
• /
• 제32권1호
• /
• pp.1-5
• /
• 2022

Diagnostics, vaccines, and drugs are indispensable tools and control measures employed to overcome infectious diseases such as coronavirus disease 2019 (COVID-19). Diagnostic tools based on RT-PCR were developed early in the COVID-19 pandemic and were urgently required for quarantine (testing, tracing and isolation). Vaccines such as mRNA vaccines and virus-vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of COVID-19. Drug development has been conducted in various ways including drug repurposing, convalescent plasma therapy, and monoclonal antibody development. Among the above efforts, this review examines COVID-19 drug development along with the related and upcoming challenges.